ÂÜÀòÂÒÂ×

Caroline Xu is the Co-Founder and CEO of ViGeneron GmbH, a position held since 2019, specializing in Next Generation Gene Therapy. Prior to this role, Caroline Xu served as Global Director of New Products and Portfolio Strategy at Sandoz BioPharmaceuticals from 2015 to 2018, and held various leadership positions within Novartis, including Head of Strategy and Operations for Novartis Oncology Emerging Growth Markets and Global Director New Products in Neurosciences. Caroline Xu's career began at McKinsey & Company as a Senior Management Consultant, followed by a role as a Medical Scientist at Columbia University Medical Center. Academically, Caroline Xu holds an MBA from Cornell Johnson Graduate School of Management, a Ph.D. in Molecular Pharmacology from the Technical University of Munich, a Master's degree in Pharmacology from the Shanghai Institute of Materia Medica, and a B.S. in Life Science from Nanjing University.